| abstract |
The present disclosure is directed to a method for treating a disease or disorder in a patient at risk of developing an NSAID-associated ulcer by administering a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof. The unit dose is designed to release at least a part of the esomeprazole independent of pH (e.g. at a pH of 0 or more) whereas the naproxen is not released until the pH or the surrounding medium is 3.5 or higher. |